Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?
CD36
CD47
fatty acids (FA)
glioblastoma (GBM)
thrombospondin-1 (TSP-1)
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
06 Jan 2022
06 Jan 2022
Historique:
received:
18
11
2021
revised:
30
12
2021
accepted:
03
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
24
2
2022
Statut:
epublish
Résumé
Glioblastoma (GBM) is one of the most aggressive tumors of the central nervous system, characterized by a wide range of inter- and intratumor heterogeneity. Accumulation of fatty acids (FA) metabolites was associated with a low survival rate in high-grade glioma patients. The diversity of brain lipids, especially polyunsaturated fatty acids (PUFAs), is greater than in all other organs and several classes of proteins, such as FA transport proteins (FATPs), and FA translocases are considered principal candidates for PUFAs transport through BBB and delivery of PUFAs to brain cells. Among these, the CD36 FA translocase promotes long-chain FA uptake as well as oxidated lipoproteins. Moreover, CD36 binds and recognizes thrombospondin-1 (TSP-1), an extracellular matrix protein that was shown to play a multifaceted role in cancer as part of the tumor microenvironment. Effects on tumor cells are mediated by TSP-1 through the interaction with CD36 as well as CD47, a member of the immunoglobulin superfamily. TSP-1/CD47 interactions have an important role in the modulation of glioma cell invasion and angiogenesis in GBM. Separately, FA, the two membrane receptors CD36, CD47, and their joint ligand TSP-1 all play a part in GBM pathogenesis. The last research has put in light their interconnection/interrelationship in order to exert a cumulative effect in the modulation of the GBM molecular network.
Identifiants
pubmed: 35054787
pii: ijms23020604
doi: 10.3390/ijms23020604
pmc: PMC8776193
pii:
doi:
Substances chimiques
CD36 Antigens
0
CD47 Antigen
0
Fatty Acids
0
Thrombospondin 1
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministerul Cercetării și Inovării
ID : PNIII.P2-2.1-PED-2019-3141, contract no 382/2020; grant no. PN 19.29.01.04 (Core Programm); COP A 1.2.3., grant ID:P_40_197/2016
Références
Oncogene. 2000 Jul 20;19(31):3508-20
pubmed: 10918609
Mediators Inflamm. 2011;2011:296069
pubmed: 21765615
Cell Death Dis. 2014 Nov 27;5:e1543
pubmed: 25429620
Immunity. 2020 Aug 18;53(2):290-302.e6
pubmed: 32768386
Prog Lipid Res. 2013 Oct;52(4):562-70
pubmed: 23981365
Cancer Res. 2004 Feb 1;64(3):920-7
pubmed: 14871821
Cancer Res. 2009 Feb 1;69(3):1212-20
pubmed: 19176395
Oncotarget. 2015 Jul 20;6(20):17981-8000
pubmed: 26046793
Nat Rev Neurosci. 2014 Dec;15(12):771-85
pubmed: 25387473
Cell Cycle. 2011 Jan 1;10(1):10-2
pubmed: 21191182
Ann Oncol. 2017 Jul 1;28(7):1448-1456
pubmed: 28407030
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
J Neurosci Res. 1999 Jun 15;56(6):565-70
pubmed: 10374811
Sci Rep. 2016 Jan 27;6:19684
pubmed: 26813769
PLoS One. 2014 May 21;9(5):e98358
pubmed: 24848268
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Lett. 2003 Feb 28;191(1):109-19
pubmed: 12609716
Oncoimmunology. 2017 Nov 6;7(2):e1391973
pubmed: 29308321
Nat Rev Cancer. 2016 Nov;16(11):732-749
pubmed: 27658529
Nat Commun. 2020 Mar 20;11(1):1508
pubmed: 32198351
Oncogene. 2010 Sep 9;29(36):5095-102
pubmed: 20581868
FASEB J. 2009 Oct;23(10):3368-76
pubmed: 19528255
Eur J Neurosci. 2021 Apr;53(8):2500-2510
pubmed: 33560561
Cancer Metastasis Rev. 1992 Nov;11(3-4):313-24
pubmed: 1384998
iScience. 2020 Aug 13;23(9):101453
pubmed: 32861192
Acta Neuropathol Commun. 2021 May 31;9(1):101
pubmed: 34059134
PLoS One. 2014 May 27;9(5):e97153
pubmed: 24865844
Toxicology. 2000 Nov 16;153(1-3):11-26
pubmed: 11090944
Oncogene. 2004 Apr 29;23(20):3642-9
pubmed: 15077189
Semin Cancer Biol. 2009 Jun;19(3):188-97
pubmed: 19429483
J Biol Chem. 2006 Sep 8;281(36):26069-80
pubmed: 16835222
Cell Stem Cell. 2010 May 7;6(5):421-32
pubmed: 20452317
Recent Pat Anticancer Drug Discov. 2018;13(2):184-200
pubmed: 29189178
Metabolites. 2020 Nov 24;10(12):
pubmed: 33255474
Br J Neurosurg. 1997 Jun;11(3):216-20
pubmed: 9231009
Biochim Biophys Acta. 1977 Feb 4;464(3):493-508
pubmed: 836823
Cell Metab. 2020 Aug 4;32(2):229-242.e8
pubmed: 32559414
J Biol Chem. 2002 Nov 8;277(45):42859-66
pubmed: 12218055
Angiogenesis. 1999;3(2):147-58
pubmed: 14517432
J Mol Neurosci. 2007 Sep;33(1):2-11
pubmed: 17901539
PLoS One. 2012;7(7):e40033
pubmed: 22808089
Immunol Rev. 2017 Mar;276(1):145-164
pubmed: 28258703
J Mol Neurosci. 2001 Apr-Jun;16(2-3):87-92; discussion 151-7
pubmed: 11478388
Theranostics. 2019 Jul 9;9(17):4893-4908
pubmed: 31410189
J Neurochem. 1998 Dec;71(6):2528-33
pubmed: 9832152
ISRN Hematol. 2013;2013:614619
pubmed: 23401787
EMBO J. 2018 Dec 3;37(23):
pubmed: 30322894
J Immunol. 1995 Mar 1;154(5):2366-74
pubmed: 7532668
Trends Cancer. 2015 Dec;1(4):252-265
pubmed: 27088132
Mol Cancer Ther. 2012 Sep;11(9):1925-35
pubmed: 22718913
Cancer Res. 2002 Feb 15;62(4):1191-5
pubmed: 11861403
Cancer Res. 2020 Apr 1;80(7):1438-1450
pubmed: 32015091
J Neurooncol. 2011 Mar;102(1):71-80
pubmed: 20617365
J Cell Mol Med. 2018 Oct;22(10):4597-4610
pubmed: 30117678
Cancers (Basel). 2019 Jan 26;11(2):
pubmed: 30691162
Blood. 2001 Dec 1;98(12):3346-52
pubmed: 11719373
J Biol Chem. 2007 May 25;282(21):15404-15
pubmed: 17416590
Cell Death Dis. 2020 Apr 20;11(4):253
pubmed: 32312953
J Clin Pathol. 2004 Jan;57(1):6-13
pubmed: 14693827
J Exp Med. 2000 May 15;191(10):1789-98
pubmed: 10811871
Sci Signal. 2009 May 26;2(72):re3
pubmed: 19471024
J Immunol. 2014 Oct 15;193(8):3914-24
pubmed: 25200950
Cancers (Basel). 2021 Oct 07;13(19):
pubmed: 34638503
Clin Epigenetics. 2017 Apr 26;9:43
pubmed: 28450971
CNS Oncol. 2013 May;2(3):289-99
pubmed: 24159371
J Biol Chem. 2010 Mar 19;285(12):8733-42
pubmed: 20056600
NMR Biomed. 2012 Nov;25(11):1234-44
pubmed: 22419606
FASEB J. 2005 Oct;19(12):1713-5
pubmed: 16037098
Sci Adv. 2019 May 22;5(5):eaaw4543
pubmed: 31131326
Stroke. 2003 Jan;34(1):177-86
pubmed: 12511771
Clin Cancer Res. 2016 Nov 1;22(21):5337-5348
pubmed: 27281560
Stem Cells Int. 2016;2016:5728438
pubmed: 26977157
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Trends Cell Biol. 2021 Feb;31(2):119-129
pubmed: 33248874
Anticancer Res. 2014 Feb;34(2):593-603
pubmed: 24510988
Nat Rev Cancer. 2020 Jan;20(1):57-70
pubmed: 31806884
Nat Commun. 2019 Mar 8;10(1):1146
pubmed: 30850588
J Biol Chem. 2011 Apr 29;286(17):14991-5002
pubmed: 21343308
Innate Immun. 2020 Feb;26(2):130-137
pubmed: 31547758
Neuro Oncol. 2016 Feb;18(2):160-72
pubmed: 26180081
Cell Mol Life Sci. 2008 Mar;65(5):728-42
pubmed: 18193160
Cell Metab. 2019 Aug 6;30(2):274-289.e5
pubmed: 31056285
Nat Rev Cancer. 2009 Mar;9(3):182-94
pubmed: 19194382
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389898
Cancer Immunol Immunother. 2021 Jul;70(7):1831-1840
pubmed: 33389016
Cell Rep. 2014 Oct 9;9(1):349-365
pubmed: 25263561
Cell Death Differ. 2000 Sep;7(9):761-72
pubmed: 11042671
Curr Pharm Des. 2020;26(18):2116-2136
pubmed: 32003661
Microvasc Res. 2007 Sep-Nov;74(2-3):90-9
pubmed: 17559888
Curr Opin Clin Nutr Metab Care. 2009 Mar;12(2):152-8
pubmed: 19202386
J Exp Clin Cancer Res. 2021 Jul 24;40(1):241
pubmed: 34303383
Cancers (Basel). 2020 Oct 26;12(11):
pubmed: 33114573
Br J Cancer. 2020 Jan;122(1):4-22
pubmed: 31819192
Clin Dev Immunol. 2013;2013:264124
pubmed: 23864876
Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61
pubmed: 19499221
J Investig Med. 2019 Apr;67(4):715-719
pubmed: 30765502
Blood. 2013 Sep 5;122(10):1822-32
pubmed: 23896411
Stem Cells. 2014 Jul;32(7):1746-58
pubmed: 24737733
J Hematol Oncol. 2017 Jan 11;10(1):12
pubmed: 28077173
Cell. 2014 Dec 18;159(7):1603-14
pubmed: 25525878
Front Pharmacol. 2020 Apr 08;11:368
pubmed: 32322199
Cell Metab. 2019 Aug 6;30(2):229-230
pubmed: 31390546
Nat Rev Cancer. 2013 Apr;13(4):227-32
pubmed: 23446547
Onco Targets Ther. 2013 Nov 29;6:1737-49
pubmed: 24348050
Matrix Biol. 2014 Jul;37:83-91
pubmed: 24476925
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Cell. 2009 Oct 16;139(2):380-92
pubmed: 19818485
Oncol Lett. 2021 Jan;21(1):22
pubmed: 33240428
Curr Proteomics. 2013 Sep;10(3):246-260
pubmed: 24228024
J Mol Neurosci. 2001 Apr-Jun;16(2-3):195-200; discussion 215-21
pubmed: 11478374
Biochim Biophys Acta Gen Subj. 2017 Oct;1861(10):2479-2484
pubmed: 28602513
J Biol Chem. 2006 Jul 28;281(30):20842-20850
pubmed: 16728400
PLoS One. 2016 Apr 19;11(4):e0153550
pubmed: 27092773
Cancer Res. 1997 May 1;57(9):1735-42
pubmed: 9135017
Anticancer Res. 2013 Apr;33(4):1429-38
pubmed: 23564783
J Cell Biol. 1997 Aug 11;138(3):707-17
pubmed: 9245797
Nitric Oxide. 2009 Aug;21(1):52-62
pubmed: 19481167
Nat Med. 2000 Jan;6(1):41-8
pubmed: 10613822
J Physiol. 2021 Mar;599(6):1745-1757
pubmed: 33347611
Cold Spring Harb Perspect Med. 2012 May;2(5):a006627
pubmed: 22553494
Int J Biochem Cell Biol. 2008;40(4):700-9
pubmed: 17996481
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298418
Antib Ther. 2020 Jul;3(3):179-192
pubmed: 33244513
Front Immunol. 2016 Jan 11;6:653
pubmed: 26793193
Carcinogenesis. 2020 Sep 24;41(9):1238-1245
pubmed: 32463428
Neurol Med Chir (Tokyo). 1995 Jul;35(7):423-30
pubmed: 7477684
Oncotarget. 2017 Jul 11;8(48):84546-84558
pubmed: 29137447
Biomed Res Int. 2018 Jul 4;2018:7801202
pubmed: 30069479
Cells. 2017 Nov 22;6(4):
pubmed: 29165393
Otolaryngol Head Neck Surg. 1987 Oct;97(4):406-8
pubmed: 3120111
Mol Ther. 2015 Feb;23(2):235-43
pubmed: 25358253
Cancer Cell. 2017 Aug 14;32(2):253-267.e5
pubmed: 28810147
Sci Rep. 2019 Dec 20;9(1):19593
pubmed: 31863022
J Hematol Oncol. 2021 Oct 30;14(1):180
pubmed: 34717705
Neuropathol Appl Neurobiol. 2010 Apr;36(3):168-82
pubmed: 20102513
Exp Neurol. 2000 Feb;161(2):621-30
pubmed: 10686081
J Biol Chem. 2015 May 15;290(20):12650-63
pubmed: 25837251
J Biol Chem. 2009 Jan 9;284(2):1116-25
pubmed: 19004835
Front Immunol. 2020 Jan 28;11:18
pubmed: 32082311
Mol Cancer Ther. 2016 Dec;15(12):3064-3076
pubmed: 27765847
Pharmacol Ther. 2015 Aug;152:54-62
pubmed: 25956465
Cancers (Basel). 2014 Jan 27;6(1):226-39
pubmed: 24473088
PLoS One. 2009 Dec 31;4(12):e8536
pubmed: 20046875
Sci Transl Med. 2010 Dec 22;2(63):63ra94
pubmed: 21178137
Crit Rev Biochem Mol Biol. 2015;50(3):212-30
pubmed: 25708195
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Sci Signal. 2009 Dec 15;2(101):ra82
pubmed: 20009104
Front Cell Dev Biol. 2017 Apr 26;5:43
pubmed: 28491867
Adv Exp Med Biol. 2020;1272:133-147
pubmed: 32845506
Oncotarget. 2010 Nov;1(7):662-73
pubmed: 21317461
J Mol Med (Berl). 2008 Sep;86(9):1025-32
pubmed: 18535813
Front Pharmacol. 2015 Oct 29;6:252
pubmed: 26578962
Genome Biol. 2017 Dec 20;18(1):234
pubmed: 29262845
J Biol Chem. 2010 Dec 10;285(50):38923-32
pubmed: 20923780
J Cell Physiol. 2008 Mar;214(3):828-37
pubmed: 17879962
PLoS One. 2018 Oct 29;13(10):e0206756
pubmed: 30372497
PLoS One. 2012;7(5):e36990
pubmed: 22606323
Nat Rev Cancer. 2014 Jan;14(1):49-60
pubmed: 24505619
Future Oncol. 2015;11(3):511-24
pubmed: 25241806